Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist.

Biotechnology

Glycomine

Glycomine's headquarters in San Carlos, CA, United States

Steven Axon

Emily Tess

Rose Marino

Peter McWilliams

Hicham Alaoui

Geoffrey Hird

Tim Mills

Hudson H. Freeze

Niall O’Donnell

Gregory Enns

Chris Starr

Jim Trenkle

Ken Harrison

Jackie Grant

Jason Hafler

The Directors team at Glycomine oversees strategic decision-making and governance, ensuring alignment with the company’s mission to develop orphan drugs for serious rare metabolic disorders. This team guides overall corporate strategy, financial oversight, regulatory compliance, and operational efficiency to advance Glycomine's therapeutic innovations.

Directors

The Leadership Team at Glycomine is responsible for setting the strategic direction and overseeing the development of innovative orphan drugs targeting rare metabolic disorders. Comprising key executives such as the Chief Technology Officer and Chief Scientific Officer, this team collaborates to drive research initiatives, foster partnerships, and ensure that the company's scientific and business strategies align to meet unmet medical needs effectively.

Leadership Team

The Clinical and Regulatory team at Glycomine oversees the design and implementation of clinical trials, ensures compliance with regulatory standards, and facilitates the approval process for orphan drugs targeting severe rare metabolic and protein misfolding disorders. This team plays a crucial role in progressing from preclinical development to market readiness, ensuring both safety and efficacy of the therapies.

Clinical and Regulatory

Glycomine

Org chart

Board & advisors

Teams

Directors

Leadership Team

Clinical and Regulatory

Offices

Glycomine

Org chart

Board & advisors

Teams

Directors

Leadership Team

Clinical and Regulatory

Offices

Related companies